FDA Brief

Warning letters Drugs

FDA warning letter to

Maypharm

High riskIssued Nov 3, 2025Posted Nov 5, 2025Center for Drug Evaluation and Research (CDER)

Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.

What happened

FDA reviewed www.maypharm.net and found it offering injectable botulinum toxin type A marketed as “BOTULAX 200 units” and “Botulax 200ui” for uses such as hyperhidrosis, blepharospasm, and deep wrinkles. FDA says the product is an unapproved new drug because no FDA-approved application is in effect, and it is misbranded because its labeling lacks adequate directions for use. No inspection was reported.

What FDA found

  1. Maypharm offered Botulax botulinum toxin for sale in the U.S. without an FDA-approved drug application.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The Botulax labeling did not include adequate directions for safe use by a layperson, so the drug is misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  3. By offering the drug to U.S. consumers, the website caused misbranded drugs to be introduced into interstate commerce.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Maypharm to stop offering unapproved and misbranded drugs to U.S. consumers, review its websites and labeling, and respond in writing within 15 working days with the steps taken and documentation. If it cannot complete corrections in that time, it must explain the delay and give a completion date.

Who should pay attention

  • U.S. clinics and med spas that buy injectables online
  • online sellers and importers of botulinum toxin products
  • consumers considering injectable treatments from foreign websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk